Novartis Discontinues Antifungal

The U.S. Food and Drug Administration (FDA) announced that Novartis has decided to discontinue two presentations of Lamisil (terbinafine) oral granules.

The company noted that the decision to discontinue the product was not because any product quality, manufacturing, or safety and efficacy concerns.

The following presentations are impacted:

125 mg (pack of 3 cartons each containing 14 packets (42 packets)); NDC 0078-0499-59

187.5 mg (pack of 3 cartons each containing 14 packets (42 packets)); NDC 0078-0500-59

Click here to read the report.

--Stephanie Vaccaro

Reference:

1. U.S. Food and Drug Administration. FDA drug shortages. www.fda.gov. Accessed May 25, 2016.